Literature DB >> 24406915

FDA halts then allows sales of Ariad's leukemia medication.

Melanie Senior.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24406915     DOI： 10.1038/nbt0114-9a

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  7 in total

1.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Authors:  Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A Repasky; Jeffrey Chen; Peter Wells; Ciarán N Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W Murray; Krister Wennerberg
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962

2.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Authors:  Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

3.  Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.

Authors:  Shuzhen Wang; Weiquan Xie; Duowei Wang; Zhigang Peng; Yan Zheng; Nan Liu; Wen Dai; Yang Wang; Zongqiang Wang; Yong Yang; Yijun Chen
Journal:  Oncotarget       Date:  2015-05-20

4.  Design, synthesis and broad-spectrum Bcr-Abl inhibitory activity of novel thiazolamide-benzamide derivatives.

Authors:  Juan Liu; Honglin Huang; Xiangping Deng; Runde Xiong; Xuan Cao; Guotao Tang; Xin Wu; Shiyu Xu; Junmei Peng
Journal:  RSC Adv       Date:  2019-01-15       Impact factor: 4.036

5.  Micellar Enhanced Spectrofluorimetric Method for the Determination of Ponatinib in Human Plasma and Urine via Cremophor RH 40 as Sensing Agent.

Authors:  Hany W Darwish; Ahmed H Bakheit; Ali Saber Abdelhameed; Amer S AlKhairallah
Journal:  Int J Anal Chem       Date:  2015-12-31       Impact factor: 1.885

6.  Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment.

Authors:  Derrick M Oaxaca; Sun Ah Yang-Reid; Jeremy A Ross; Georgialina Rodriguez; Joan G Staniswalis; Robert A Kirken
Journal:  Tumour Biol       Date:  2016-07-21

7.  Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors.

Authors:  Peipei Xu; Dan Guo; Xiaoyan Shao; Miaoxin Peng; Bing Chen
Journal:  Onco Targets Ther       Date:  2017-09-25       Impact factor: 4.147
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.